Cytori Therapeutics Inc. (USA)  

(Public, NASDAQ:CYTX)   Watch this stock  
Find more results for CYTX
-0.02 (-1.65%)
Real-time:   11:31AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.04 - 1.07
52 week 1.02 - 3.93
Open 1.06
Vol / Avg. 226,439.00/523,421.00
Mkt cap 84.36M
P/E     -
Div/yield     -
EPS -0.52
Shares 79.54M
Beta 2.36
Inst. own 22%
Sep 22, 2014
Cytori Therapeutics Inc at Maxim Group's Institutional NYC BioDefense Mini-Conference Add to calendar
Jul 31, 2014
Cytori Therapeutics Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -916.19% -214.64%
Operating margin -827.65% -257.35%
EBITD margin - -260.06%
Return on average assets -122.16% -61.37%
Return on average equity -2639.33% -546.09%
Employees 115 -
CDP Score - -


3020 Callan Road
United States - Map
+1-858-4580900 (Phone)
+1-858-4580994 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cytori Therapeutics, Inc. develops cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The advanced therapeutic application in the Company's clinical pipeline is for cardiovascular disease. The Company�s products include Celbrush, Puregraft, and Cytori LipoBank. The Celbrush is available in the 10 milliliter and 3 milliliter sizes and is used in conjunction with a Soft-Ject Syringe in the corresponding size. The Puregraft System is developed for autologous fat grafting and aesthetic body contouring. The Puregraft System is available in two sizes: 250 milliliter, which processes 50-250 milliliter of tissue, and 850 milliliter, which processes 200-850 milliliter of tissue. The Cytori LipoBank is a GTP-compliant cryopreservation system that offers a long-term storage option for viable adipose tissue after a single liposuction.

Officers and directors

David M. Rickey Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Marc H. Hedrick M.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Tiago Girao Chief Financial Officer, Vice President - Finance
Age: 35
Bio & Compensation  - Reuters
Clyde W. Shores Executive Vice President - Marketing & Sales
Age: 54
Bio & Compensation  - Reuters
Steven Kesten M.D. Executive Vice President, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Lloyd H. Dean Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 65
Bio & Compensation  - Reuters
Paul W. Hawran CPA Independent Director
Age: 62
Bio & Compensation  - Reuters
E. Carmack Holmes M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 63
Bio & Compensation  - Reuters